Systemic Chemotherapy in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery: Systematic Review and Meta-Analysis
Open Access
Abstract
Background. For patients with colorectal cancer (CRC) peritoneal metastases (PM) who are eligible for cytoreductive surgery (CRS), the indication and timing of systemic chemotherapy (SC) are still under debate. This study aims to analyze the role of pre, post or perioperative SC on the survival and surgical complications of patients treated with CRS-HIPEC. Methods. After a systematic search in MEDLINE, Cochrane Database of Systematic Reviews, Scopus, Web of Science and Embase, a meta-analysis was performed to compare postoperative complications, disease-free survival (DFS) and overall survival (OS) according to SC administration and timing. PROSPERO: CRD42023478977. Results. Of 1203 studies screened, 15 were included in the meta-analysis (4523 patients). Post-operative SC was associated with increased overall survival (post-SC vs. no post-SC: HR 0.81, p = 0.00001, I2 = 0%; pre-SC vs. post-SC: HR 0.65, p = 0.01, I2 = 28%), whereas SC (pre or post) or pre-SC compared to surgery alone was not (SC vs. no SC: p = 0.29, I2 = 80%; pre-SC vs. no pre-SC: p = 0.59, I2 = 58%). Similar results were seen for DFS. SC was not associated with an increased complication rate (p = 0.47, I2 = 64%). Conclusions. Systemic chemotherapy administration in patients undergoing radical surgery for colorectal peritoneal metastases is associated with increased survival only in the adjuvant/post-operative setting. Considering the limitations of the included studies, further trials are needed to answer this unresolved question.Keywords
Funding Information
- Italian Ministry of Health “Ricerca Corrente 2024”
This publication has 46 references indexed in Scilit:
- Perioperative chemotherapy in colorectal cancer with peritoneal metastases: a global propensity score matched studyeClinicalMedicine, 2022
- A total neoadjuvant chemotherapy approach is associated with improved recurrence‐free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPECJournal of Surgical Oncology, 2022
- Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal MetastasesJAMA Surgery, 2021
- Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC TrialClinical Colorectal Cancer, 2018
- Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic reviewCritical Reviews in Oncology/Hematology, 2017
- Patterns of metachronous metastases after curative treatment of colorectal cancerCancer Epidemiology, 2014
- Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2012
- Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysisEuropean Journal of Cancer, 2010
- Phase II studies: International registry of colorectal carcinomatosisEuropean Journal of Surgical Oncology, 2006
- Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal originBritish Journal of Surgery, 2004